Related references
Note: Only part of the references are listed.Sequential Therapy With Sorafenib and Sunitinib in Renal Cell Carcinoma
Arkadiusz Z. Dudek et al.
CANCER (2009)
Phase I Trial of 2-Methoxyestradiol NanoCrystal Dispersion in Advanced Solid Malignancies
Amye J. Tevaarwerk et al.
CLINICAL CANCER RESEARCH (2009)
Activity of 2 methoxyestradiol (Panzem® NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: A Hoosier Oncology Group trial
Daniela Matei et al.
GYNECOLOGIC ONCOLOGY (2009)
Sequential Use of the Tyrosine Kinase Inhibitors Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma: A Retrospective Outcome Analysis
Christian Eichelberg et al.
EUROPEAN UROLOGY (2008)
Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy
Ila Tamaskar et al.
JOURNAL OF UROLOGY (2008)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors
WL Dahut et al.
CANCER BIOLOGY & THERAPY (2006)
A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer
C Sweeney et al.
CLINICAL CANCER RESEARCH (2005)
2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF
NJ Mabjeesh et al.
CANCER CELL (2003)
2-methoxyestradiol, a promising anticancer agent
NJ Lakhani et al.
PHARMACOTHERAPY (2003)
Mechanism of action of 2-methoxyestradiol: new developments
SL Mooberry
DRUG RESISTANCE UPDATES (2003)
Mucoadhesive nanoparticulate systems for peptide drug delivery
H Takeuchi et al.
ADVANCED DRUG DELIVERY REVIEWS (2001)
Share Paper
